semaglutide news today october 2025 Most quit breakthrough weight-loss drug within a year Obesity drugs improve health but

Despite these advances, most individuals do not achieve optimal cardiometabolic outcomes with monotherapy alone [12,13,14]

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Choose carefully

Mild stinging during injection is normal

Following up with your healthcare provider for regular monitoring and discussing concerns is essential

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that stimulates insulin secretion, delays gastric emptying, and reduces appetite, making it highly effective for weight loss and managing Type 2 diabetes